10 Stocks With At Least $10 Million In Insider Sales Recently

5. Eli Lilly and Company (NYSE:LLY)

Highest Individual Sale: $19,507,205.25

Number of Sales Above $10 million: 24

Market Capitalization: $835.05 billion

In the middle of this list of 10 stocks with $10 million in insider sales recently is a multinational pharmaceutical firm, Eli Lilly and Company. Commonly known as Lilly, the Indianapolis, Indiana-headquartered company has offices in 18 countries and its products have reached approximately 125 countries worldwide. It is also one of the top 10 stocks to buy according to Lone Pine Capital.

Lilly is known for its clinical depression drugs Prozac (1986), Cymbalta (2004), and its antipsychotic medication Zyprexa (1996). Its primary revenue drivers are the diabetes drugs Humalog (1996) and Trulicity (2014).

Since the beginning of the year, one insider made 24 sales of Eli Lilly shares. One of the transactions was worth $19.51 million, during which the insider sold 21,025 shares at a price of $927.81 per share. Currently, the stock is trading at $929.72, having gained 20.43% year-to-date.

Recently, Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the U.S. This brings the company’s total capital expansion commitments to more than $50 billion since 2020.

Last week, the company also confirmed that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a reversible Bruton’s tyrosine kinase (BTK) inhibitor. The treatment is recommended for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have previously been treated with a BTK inhibitor. The news caused its shares to jump 2.713%, from $905.16 to $929.72 per share.

Twenty analysts have an average “Moderate Buy” rating on Lilly stock, with a price target of $1,007.50 per share, according to MarketBeat.